GI
Giant Industries, Inc.
Set alert
- Open
- 8.00
- Prev close
- 8.00
- Mkt cap
- 0
- Vol
- 14.18K
- Avg vol
- 128.52K
- EPS
- -3.59
- P/E
- -2.23
More statistics
- Low
- 7.95
- High
- 8.00
- Earnings
- Nov 24, 2016
News
5 days ago gurufocus.com
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
5 days ago gurufocus.com
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
1 week ago gurufocus.com
Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patien
Sun Pharma Announces UNLOXCYTÂ (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneou
2 months ago gurufocus.com
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing lifeâchanging therapies for people living w
3 months ago gurufocus.com
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significan
3 months ago gurufocus.com
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarciba
4 months ago gurufocus.com
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
[url="]Pfizer Inc.[/url] (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF'3944), an investigational, potential f
5 months ago gurufocus.com
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
5 months ago gurufocus.com
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living wi
5 months ago gurufocus.com
Alight Adds Cylinder and Leap to Partner Network
Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth, leave and point solutions, today announced the expansion of its Alight
-
9 years ago benzinga.com
Earnings Scheduled For April 11, 2017
Earnings Scheduled For April 11, 2017